BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bao Y, Oguz G, Lee WC, Lee PL, Ghosh K, Li J, Wang P, Lobie PE, Ehmsen S, Ditzel HJ, Wong A, Tan EY, Lee SC, Yu Q. EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy.Nat Commun. 2020;11:5878. [PMID: 33208750 DOI: 10.1038/s41467-020-19704-x] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
Number Citing Articles
1 Chava S, Bugide S, Malvi P, Gupta R. Co-targeting of specific epigenetic regulators in combination with CDC7 potently inhibit melanoma growth. iScience 2022;25:104752. [DOI: 10.1016/j.isci.2022.104752] [Reference Citation Analysis]
2 Vishwanath D, Girimanchanaika SS, Dukanya D, Rangappa S, Yang JR, Pandey V, Lobie PE, Basappa B. Design and Activity of Novel Oxadiazole Based Compounds That Target Poly(ADP-ribose) Polymerase. Molecules 2022;27:703. [PMID: 35163965 DOI: 10.3390/molecules27030703] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Mirzaei S, Gholami MH, Hushmandi K, Hashemi F, Zabolian A, Canadas I, Zarrabi A, Nabavi N, Aref AR, Crea F, Wang Y, Ashrafizadeh M, Kumar AP. The long and short non-coding RNAs modulating EZH2 signaling in cancer. J Hematol Oncol 2022;15:18. [PMID: 35236381 DOI: 10.1186/s13045-022-01235-1] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
4 Ong LT, Lee WC, Ma S, Oguz G, Niu Z, Bao Y, Yusuf M, Lee PL, Goh JY, Wang P, Yong KSM, Chen Q, Wang W, Ramasamy A, Hoon DSB, Ditzel HJ, Tan EY, Lee SC, Yu Q. IFI16-dependent STING signaling is a crucial regulator of anti-HER2 immune response in HER2+ breast cancer. Proc Natl Acad Sci U S A 2022;119:e2201376119. [PMID: 35878022 DOI: 10.1073/pnas.2201376119] [Reference Citation Analysis]
5 Hollenstein DM, Gérecová G, Romanov N, Ferrari J, Veis J, Janschitz M, Beyer R, Schüller C, Ogris E, Hartl M, Ammerer G, Reiter W. A phosphatase-centric mechanism drives stress signaling response. EMBO Rep 2021;22:e52476. [PMID: 34558777 DOI: 10.15252/embr.202152476] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
6 Chen F, Liu J, Flight RM, Naughton KJ, Lukyanchuk A, Edgin AR, Song X, Zhang H, Wong KK, Moseley HNB, Wang C, Brainson CF. Cellular Origins of EGFR-Driven Lung Cancer Cells Determine Sensitivity to Therapy. Adv Sci (Weinh) 2021;8:e2101999. [PMID: 34622577 DOI: 10.1002/advs.202101999] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Cheng X, Zhao JX, Dong F, Cao XC. ARID1A Mutation in Metastatic Breast Cancer: A Potential Therapeutic Target. Front Oncol 2021;11:759577. [PMID: 34804958 DOI: 10.3389/fonc.2021.759577] [Reference Citation Analysis]
8 Lohiya G, Katti DS. Carboxylated chitosan-mediated improved efficacy of mesoporous silica nanoparticle-based targeted drug delivery system for breast cancer therapy. Carbohydr Polym 2022;277:118822. [PMID: 34893239 DOI: 10.1016/j.carbpol.2021.118822] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
9 Liu XY, Guo CH, Xi ZY, Xu XQ, Zhao QY, Li LS, Wang Y. Histone methylation in pancreatic cancer and its clinical implications. World J Gastroenterol 2021; 27(36): 6004-6024 [PMID: 34629816 DOI: 10.3748/wjg.v27.i36.6004] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
10 Adibfar S, Elveny M, Kashikova HS, Mikhailova MV, Farhangnia P, Vakili-Samiani S, Tarokhian H, Jadidi-Niaragh F. The molecular mechanisms and therapeutic potential of EZH2 in breast cancer. Life Sci 2021;286:120047. [PMID: 34653429 DOI: 10.1016/j.lfs.2021.120047] [Reference Citation Analysis]